Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
NCT01294878
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Interstitial Cystitis
Painful Bladder Syndrome
Interventions
DRUG:
omalizumab
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia